Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C


Altunok E. S. , SAYAN M. , AKHAN S. , AYGEN B., YILDIZ O., Koruk S. T. , et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, cilt.50, ss.1-5, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 50
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.ijid.2016.07.003
  • Dergi Adı: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
  • Sayfa Sayısı: ss.1-5

Özet

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.